Recursion Pharmaceuticals (RXRX) Capital Expenditures (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Capital Expenditures data on file, last reported at $258000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 85.92% year-over-year to $258000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 million (down 117.74% YoY) and the FY2024 annual result came in at $13.7 million, up 14.55% from the prior year.
• Capital Expenditures improved to $258000.0 in Q1 2026, from -$5.2 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $12.0 million in Q4 2023 to a low of -$6.1 million in Q2 2024.
• A 5-year average of $1.6 million and a median of $258000.0 in 2026 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures slumped 2976.79% — and 2024, when it surged 197566.67%.
• Tracing RXRX's Capital Expenditures over 5 years: stood at -$2.5 million in 2022, then surged by 577.82% to $12.0 million in 2023, then slumped by 89.14% to $1.3 million in 2024, then sank by 502.54% to -$5.2 million in 2025, then surged by 104.94% to $258000.0 in 2026.
• The last three Capital Expenditures figures came in at $258000.0 (Q1 2026), -$5.2 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.